Latest Articles
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) - The Manila Times
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR) The Manila Times
Published: June 24, 2026, 10:48 a.m.
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer - Targeted Oncology
Puxitatug Samrotecan Hits 60% Response Rate in Platinum- and IO-Pretreated Endometrial Cancer Targeted Oncology
Published: June 19, 2026, 5:05 p.m.
'If you hate this country, leave': Hanson makes fiery Press Club debut with familiar targets in her sights - psnews.com.au
'If you hate this country, leave': Hanson makes fiery Press Club debut with familiar targets in her sights psnews.com.au
Published: June 18, 2026, 4:17 a.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - riauone.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 riauone.com
Published: June 15, 2026, 12:29 p.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - The Manila Times
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 The Manila Times
Published: June 14, 2026, 10:21 p.m.
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 - NTB Kommunikasjon
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 NTB Kommunikasjon
Published: June 14, 2026, 10:05 p.m.
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis - TradingView
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis TradingView
Published: June 9, 2026, 8:01 p.m.
New targeted drug brings hope for women with hard-to-treat ovarian cancer - The Eastleigh Voice
New targeted drug brings hope for women with hard-to-treat ovarian cancer The Eastleigh Voice
Published: June 5, 2026, 4:16 a.m.
Dostarlimab/Chemo Shows Curative Potential in dMMR/MSI-H Advanced Endometrial Cancer - Targeted Oncology
Dostarlimab/Chemo Shows Curative Potential in dMMR/MSI-H Advanced Endometrial Cancer Targeted Oncology
Published: May 29, 2026, 10:11 p.m.
Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Pfizer targets VEGF bispecific white space | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Published: May 21, 2026, 12:46 p.m.
Link copied to clipboard!